Valuation

What Is a Healthtech Company Worth in 2026?

Published by ProCloser Research · Reviewed by Aaron Whittaker, Founder Published September 10, 2026 | Updated October 12, 2026 Deal data as of October 12, 2026

What changed in October 2026: added a new FAQ on cross-border deal share and refreshed the tracked deal counts from the ProCloser Tech M&A Deal Index.

The data answer

The ProCloser Tech M&A Deal Index tracked 127 healthtech acquisitions announced in 2026, each documented to a public source. 17 disclosed a price; the median disclosed value is $105M. That median describes the visible top of the market, because disclosure skews toward large transactions. What your company is worth depends on the drivers below, and the honest way to estimate it is against real comparable deals plus your own numbers in the valuation calculator.

What the 2026 deal data shows

127

Tracked 2026 healthtech deals
ProCloser Deal Index, primary-source documented

$105M

Median disclosed value
Across 17 deals that published a price

82%

Strategic buyers
Share of deals with identified buyer type

Healthtech valuations hinge on reimbursement exposure and compliance posture. Software sold to providers on subscription trades like vertical SaaS; anything touching claims, clinical data or patient billing carries regulatory diligence that changes both timeline and price.

The largest priced healthtech deals of 2026

Of the 127 healthtech acquisitions the ProCloser Tech M&A Deal Index tracked through Oct 12, 2026, 17 (13%) disclosed a price. The five largest are below, each linked to its public source.

Announced	Target	Buyer	Value	Source
May 18, 2026	Press Ganey Forsta	Qualtrics	$6.75B	prnewswire.com
Jul 23, 2026	ArisGlobal	Dassault Systèmes	$1.80B	globenewswire.com
May 7, 2026	PathAI	Roche	$750M	globenewswire.com
Aug 18, 2026	Weave	Francisco Partners	$650M	sec.gov
Jun 8, 2026	Kneat	Thoma Bravo	$474M	globenewswire.com

What actually moves the number

Revenue model: subscription software versus reimbursement-linked revenue
HIPAA and data-handling posture, verified in diligence
Integration depth with EHR systems and payer workflows
Evidence of clinical or financial outcomes customers can defend

Deals here take longer than plain software transactions; plan the diligence file early.

How to get a real estimate

Three steps beat any rule of thumb. First, run your revenue, EBITDA and sector through the ProCloser valuation calculator for an indicative range. Second, look at actual comparable transactions in the deal index rather than survey multiples. Third, remember that the spread between a bilateral offer and a competitive process is usually larger than the spread between valuation methods; our advisor rankings cover who runs those processes for companies like yours.

Want a Number for Your Business?

Run the calculator for an indicative range, or tell us your sector, size and timeline and we will match you with vetted advisors who can value it properly. Free to sellers, no retainer required.

Run the Valuation Calculator →

Frequently Asked Questions

What is the average sale price of a healthtech company in 2026?

Across 127 tracked 2026 healthtech acquisitions in the ProCloser Tech M&A Deal Index, 17 disclosed a price, with a median disclosed value of $105M. Treat that number carefully: companies that disclose skew large and public. Most founder-scale deals never publish a price, so the true market median sits well below the disclosed one.

Who buys healthtech companies?

In tracked 2026 transactions, strategic acquirers accounted for roughly 82% of healthtech deals with an identified buyer type, with private equity taking most of the rest. 21 of the 127 tracked deals crossed a border, so a well-run process usually includes foreign buyers.

Which healthtech acquisitions had the highest disclosed price in 2026?

In the ProCloser Tech M&A Deal Index, the largest disclosed healthtech prices through Oct 12, 2026 were Press Ganey Forsta, bought by Qualtrics for $6.75B; ArisGlobal, bought by Dassault Systèmes for $1.80B; PathAI, bought by Roche for $750M. 17 of 127 tracked healthtech deals (13%) disclosed any price, so these describe the top of the market, not a typical sale.

Why do disclosed deal values overstate what typical companies sell for?

Because disclosure is selective. Press releases publish prices when a public company, large sponsor or regulator requires it, which concentrates disclosure among the biggest transactions. Founder-scale deals routinely close without a published number. Any median built on disclosed values describes the visible top of the market, not the middle.

How many 2026 healthtech deals crossed a border?

21 of the 127 tracked 2026 healthtech acquisitions involved a buyer or seller headquartered in a different country, 17% of the tracked set. A cross-border share that high means a seller who limits outreach to domestic buyers is skipping a meaningful slice of the realistic buyer pool.

ProCloser.ai is not a registered investment adviser, broker-dealer or financial planner, and nothing on this page is investment, legal or tax advice. Rankings are editorially determined from publicly available information under the ProCloser TrustRank methodology; positions are never sold, and any sponsored placement is clearly labeled. ProCloser may receive compensation when you connect with an advisor through our matching service. See our Advertiser Disclosure.